Back
Amarin Corp PLC 10K Form
Sell
35
AMRN
Amarin Corp PLC
Last Price:
$0.48
Seasonality Move:
9.36%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-01 | 10Q | AMRN/Amarin Corp PLC Quarterly |
2023-11-01 | 10Q | AMRN/Amarin Corp PLC Quarterly |
2023-08-02 | 10Q | AMRN/Amarin Corp PLC Quarterly |
2023-05-03 | 10Q | AMRN/Amarin Corp PLC Quarterly |
2022-10-27 | 10Q | AMRN/Amarin Corp PLC Quarterly |
2022-08-03 | 10Q | AMRN/Amarin Corp PLC Quarterly |
Receive AMRN News And Ratings
See the #1 stock for the next 7 days that we like better than AMRN
AMRN Financial Statistics
Sales & Book Value
Annual Sales: | $306.9M |
---|---|
Cash Flow: | $-2.4M |
Price / Cash Flow: | 272.84 |
Annual Sales: | $1.29 |
Price / Book: | 0.37 |
Profitability
EPS (TTM): | -0.09630 |
---|---|
Net Income (TTM): | $-39.3M |
Gross Margin: | $165.5M |
Return on Equity: | -7.2% |
Return on Assets: | -4.91% |
Amarin Corp PLC Earnings Forecast
Key Amarin Corp PLC Financial Ratios
-
The Gross Profit Margin over the past 31 years for AMRN is 53.94%.
-
The Selling, General & Administrative Expenses for AMRN have been equal to 65.15% of Gross Profit Margin.
-
The Research & Development expenses have been 7.24% of Revenue.
-
The Interest Expense is -0.01% of Operating Income.
-
The Net Earning history of AMRN is -19.26% of Total Revenues.
-
Per Share Earnings over the last 31 years have been positive in 17 years.
Amarin Corp PLC Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | AMRN |
CUSIP: | 023111 |
Website: | amarincorp.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 3.23 |
Quick Ratio: | 2.08 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
AMRN Technical Analysis vs Fundamental Analysis
Sell
35
Amarin Corp PLC (AMRN)
is a Sell
Is Amarin Corp PLC a Buy or a Sell?
-
Amarin Corp PLC stock is rated a SellThe current Amarin Corp PLC [AMRN] share price is $0.48. The Score for AMRN is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.